TMO Thermo Fisher Scientific
FY2025 10-K
Thermo Fisher Scientific (TMO) filed its fiscal year 2025 10-K annual report with the SEC on Feb 26, 2026. This page provides AI-powered analysis of the filing, including business overview, management discussion, risk factors, and key financial metrics from XBRL data.
AI Filing AnalysisFY2025 10-K
Business Overview
- • Core business: Life sciences tools & services conglomerate serving pharma/biotech, academic, industrial, and healthcare markets across four segments
- • Sept 2025 acquisition of Solventum's filtration/separation business (~$4.04B total acquisition spend in 2025) added bioproduction purification tech plus industrial filtration for battery, semiconductor, and medical device markets
Management Discussion & Analysis
- • Revenue $44,556M, up ~3.9% YoY from $42,879M; Lab Products & Biopharma Services largest segment at $23,984M
- • GAAP operating margin 17.4% vs 17.1%; adjusted operating margin 22.7% vs 22.6%; driven by productivity gains offset by tariffs and mix
Risk Factors
- • China regulations requiring local suppliers plus tariff volatility directly threaten international revenues, with currency translation adding $0.37B to 2025 revenues
- • Outstanding debt ~$39.38B with $5.00B revolving credit facility; covenant requires minimum 3.5:1.0 Consolidated Net Interest Coverage Ratio
Financial SummaryXBRL
Revenue
$44.6B
Net Income
$6.7B
Operating Margin
17.4%
Net Margin
15.0%
ROE
12.6%
Total Assets
$110.3B
EPS (Diluted)
$17.74
Operating Cash Flow
$7.8B
Source: XBRL data from Thermo Fisher Scientific FY2025 10-K filing on SEC EDGAR. All figures in USD.
Get deeper insights on Thermo Fisher Scientific
Access full AI analysis, insider trading data, fund holdings, and cross-signal detection on SignalX.